RSS-Feed abonnieren
DOI: 10.1055/a-2099-7560
Pathogenese der Schizophrenie(n)
Bei Schizophrenie(n) handelt es sich um eine psychische Störung, die sowohl auf phänomenologischer als auch auf neurobiologischer Ebene durch ausgeprägte Heterogenität gekennzeichnet ist. Deren diagnostische Entflechtung würde zu einer präziseren Behandlung und Verbesserung der Prognose bei Menschen mit Schizophrenie führen. Hierfür benötigt man ein tieferes Verständnis über die pathophysiologischen Mechanismen der Schizophrenie(n).
Abstract
Schizophrenia is a mental disorder characterized by marked heterogeneity at both the phenomenological and neurobiological levels. Its diagnostic disentanglement would lead to more precise treatment and improved prognosis in people with schizophrenia. For this, a deeper understanding of the pathophysiological mechanisms of schizophrenia is needed.
Publikationsverlauf
Artikel online veröffentlicht:
19. September 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14,70469 Stuttgart,
Germany
-
Literatur
- 1 Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 388: 86-97 DOI: 10.1016/S0140-6736(15)01121-6.
- 2 Smeland OB, Frei O, Dale AM. et al. The polygenic architecture of schizophrenia – rethinking pathogenesis and nosology. Nat Rev Neurol 2020; 16: 366-379 DOI: 10.1038/s41582-020-0364-0.
- 3 Kahn RS, Sommer IE, Murray RM. et al. Schizophrenia. Nat Rev Dis Primers 2015; 1: 15067 DOI: 10.1038/nrdp.2015.67.
- 4 Leitliniengruppe DeVHfd. S3-Leitlinie Schizophrenie. Langfassung, 2019, Version 1.0, zuletzt geändert am 15.März 2019. Zugriff am 07. September 2022 https://www.awmf.org/leitlinien/detail/ll/038-009.html
- 5 Bernard A, Fischer RWB. Schizophrenia in adults: Clinical manifestations, course, assessment, and diagnosis. Zugriff am 07. September 2022 https://www.uptodate.com/contents/schizophrenia-in-adults-clinical-manifestations-course-assessment-and-diagnosis?csi=c885716c-8f8c-4a31-89ae-97aa4472594b&source=contentShare
- 6 McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia – an overview. JAMA Psy 2020; 77: 201-210 DOI: 10.1001/jamapsychiatry.2019.3360.
- 7 Murray RM, Bhavsar V, Tripoli G. et al. 30 years on: How the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis. Schizophr Bull 2017; 43: 1190-1196 DOI: 10.1093/schbul/sbx121.
- 8 Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci 2017; 18: 727-740 DOI: 10.1038/nrn.2017.125.
- 9 Buck SA, Quincy Erickson-Oberg M, Logan RW. et al. Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia. Mol Psychiatry 2022; DOI: 10.1038/s41380-022-01649-w.
- 10 McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment. World Psych 2020; 19: 15-33 DOI: 10.1002/wps.20693.
- 11 Sapienza J, Bosia M, Spangaro M. et al. Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes. Mol Psych 2022; DOI: 10.1038/s41380-022-01721-5.
- 12 Khandaker GM, Cousins L, Deakin J. et al. Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. Lancet Psych 2015; 2: 258-270 DOI: 10.1016/S2215-0366(14)00122-9.
- 13 van Kesteren CF, Gremmels H, de Witte LD. et al. Immune involvement in the pathogenesis of schizophrenia: A metaanalysis on postmortem brain studies. Transl Psych 2017; 7: e1075 DOI: 10.1038/tp.2017.4.
- 14 Pollak TA, Drndarski S, Stone JM. et al. The blood-brain barrier in psychosis. Lancet Psych 2018; 5: 79-92 DOI: 10.1016/S2215-0366(17)30293-6.
- 15 Bloomfield PS, Selvaraj S, Veronese M. et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [(11)C]PBR28 PET brain imaging study. Am J Psych 2016; 173: 44-52 DOI: 10.1176/appi.ajp.2015.14101358.